P2RY12 and atrial fibrillation: Our network meta-analysis corroborates the finding that dual therapy with an NOAC and P2Y12 inhibitor superior to triple therapy in AF patients undergoing PCI; This conclusion is based on the observed 46% reduction in major or minor TIMI bleeding with similar MACE outcomes.